The Trump administration secured commitments from top pharmaceutical companies to work together to develop a vaccine and treatments to fight the coronavirus.
From the leaders of marketing teams to medical affairs, pharma executives are increasingly required to do more with less. While this is true across industries, the U.S. biopharma industry is faced with unique headwinds.
Modern pharmacies have lost the personal touch that ma and pa shops once had as they grapple with a growing patient volume. Pharmaceutical executives would be wise to abandon their struggling system and adopt an entrepreneurial mindset.